SCHEMBL7535547

SCHEMBL7535547

COc1ccc(NS(=O)(=O)c2cccc(Cl)c2[N+](=O)[O-])cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.48
▸ LMNA P02545 5/20 0.48
▸ MEN1 O00255 7/20 0.47
▸ KMT2A Q03164 7/20 0.47
▸ SLC22A12 Q96S37 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ USP2 O75604 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ PKM P14618 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ THRB P10828 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ MAPT P10636 3/20 0.43
▸ HSD17B2 P37059 2/20 0.43
▸ HTT P42858 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6681330 0.78 ALDH1A1 (0.59) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL7535790 0.76 L3MBTL1 (0.45) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL27579266 0.76 CA12 (0.51) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL7534716 0.74 ALDH1A1 (0.63) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL7235930 0.71 SMN1; SMN2 (0.50) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL6674654 0.71 ALDH1A1 (0.59) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL6675569 0.71 ALDH1A1 (0.59) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL16680267 0.71 SMN1; SMN2 (0.67) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL7171823 0.71 HTR6 (0.62) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL6680382 0.70 SMN1; SMN2 (0.52) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 ALDH1A1 1173/4885LMNA 2006/4885MEN1 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback